Healthy Expectancy Through Routine Antenatal STI Screening

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age15+
SponsorAdriane Wynn

About this trial

This study will evaluate whether routine screening and treatment for two common sexually transmitted infections, chlamydia and gonorrhoea, during pregnancy can reduce preterm birth and other poor birth outcomes in Botswana, and whether this approach is affordable and cost-effective for the health system.

About 2,000 pregnant women attending their first antenatal care visit at up to 10 government clinics in Botswana will be invited to join the study. All women will first receive the usual antenatal care services provided in Botswana, including routine health checks and HIV and syphilis testing. Women who enroll in the study will be randomly assigned to one of two groups:

1. Standard of care group: Women receive routine antenatal care only. 2. Intervention group: In addition to routine antenatal care, women are screened for chlamydia and gonorrhoea using self-collected vaginal swabs at their first antenatal care visit and again in the third trimester.

The main outcome of the study is whether screening and treating chlamydia and gonorrhoeae reduces preterm birth (before 37 weeks). Other outcomes include low birth weight, very preterm birth, and maternal health conditions.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Asymptomatic for cervicovaginitis at first ANC (i.e., not syndromically treated for an STI by clinic midwives at first ANC)

Age ≥ 15 years

Currently pregnant

≤20 weeks gestation (based on gestational age in obstetric record or last menstrual period if gestational age missing from record)

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Chlamydia trachomatis and Neisseria gonorrhoeae screening

    Diagnostic test

    Screening with Xpert® CT/NG assay at first antenatal care and third trimester

Treatment groups

2,000 Participants
are divided into 2 treatment groups
Group A: Standard of CareNo intervention 0 interventions
Group B: InterventionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Preterm birth

\<37 weeks gestation

Time frame
Weeks gestation at birth, calculated from delivery date and date of last menstrual period and first trimester ultrasound dating

Secondary outcomes

1

Infant Outcomes: low birth weight, and a composite measure of preterm or low birth weight; very preterm birth; and preterm birth sub-types.

Low birth weight: \<2500g Very preterm birth: \<32 weeks gestation Preterm birth sub-types: spontaneous, medically indicated

Time frame
Number of weeks gestation at birth, calculated from delivery date and date of last menstrual period and first trimester ultrasound dating.
2

Pregnancy/maternal outcomes: gestational hypertension, preeclampsia, incident HIV infection.

Gestational hypertension: one-two elevations of systolic 140+ or diastolic blood pressure 90+ after 20 weeks pregnancy Preeclampsia: hypertension with substantial proteinuria after 20 weeks pregnancy

Time frame
First trimester ANC through post-delivery obstetrical follow-up

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Adriane Wynn

Lead sponsor

University of California, San Diego

Sponsor institution

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Collaborator

Botswana Harvard AIDS Institute Partnership

Collaborator